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ABSTRACT
Proteins encoded by a 9.5-kb DNA segment, termed the region of difference (RD), of Mycobacterium
tuberculosis have been demonstrated to be important in bacterial virulence, vaccine development and the
design of diagnostic reagents. This study evaluated the immunogenic properties of Rv3425, a member of
the PPE family of proteins, encoded by an open reading frame found in RD11 of M. tuberculosis, in
comparison with two other well-known antigens, the early secreted antigen target 6 (ESAT-6) and the
10-kDa culture ﬁltrate protein (CFP-10). RT-PCR demonstrated that Rv3425 mRNA is expressed in
liquid culture by M. tuberculosis H37Rv. When tested in a conventional ELISA in the form of a His-
tagged recombinant protein, Rv3425 revealed a statistically signiﬁcant antigenic distinction between
healthy bacille Calmette–Gue´rin (BCG)-vaccinated controls and tuberculosis (TB) patients (p <0.0001).
The anti-IgG response to recombinant Rv3425 was almost equal to that for CFP-10, and was higher than
that for ESAT-6. The results highlight the immunosensitive and immunospeciﬁc nature of Rv3425,
which shows promise for use in the serodiagnosis of TB.
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INTRODUCTION
Tuberculosis (TB), caused by Mycobacterium tuber-
culosis, is a major public health problem world-
wide, with 8 million new cases and 2–3 million
deaths annually, despite the use of the bacille
Calmette-Gue´rin (BCG) vaccine and effective
antibiotics [1]. Indeed, the problem has been
exacerbated by the increasing emergence of
multidrug-resistant strains and co-infection with
human immunodeﬁciency virus (HIV) [2–4]. The
increasing threat of this disease has emphasised
the need for basic and applied research aimed
at developing new drugs, improving diagnosis
and vaccines, and gaining a better understanding
of host–parasite interactions. Currently, diagnosis
of TB relies mainly on clinical examination and
radiographical ﬁndings, conﬁrmed by sputum
smear microscopy and bacterial culture. How-
ever, culture of M. tuberculosis requires up to 6–
8 weeks, so that conﬁrmation of the diagnosis
often depends on sputum smear microscopy,
which has a sensitivity of only 50–60% [5].
Several rapid diagnostic techniques have been
investigated in recent years to determine their
ability to improve the diagnosis of TB. These
techniques include the detection ofM. tuberculosis
in clinical specimens by PCR, as well as immune
reactions based on the cell-mediated immune
response (CMI) or on humoral immune re-
sponses. In-vitro tests based on CMI make poss-
ible the early detection of individuals with latent
infection, and are of great importance for contact
tracing and screening of high-risk groups in a
setting of low endemicity [6,7]. However, this
method is not an ideal alternative to culture and
microscopy in developing countries, as large
proportions of the populations in such countries
are likely to harbour latent infection with
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M. tuberculosis [8]. A serological test would be an
attractive alternative diagnostic method; such a
test would be rapid, easy to perform and user-
friendly, and could be implemented easily in the
conditions found in developing countries as,
unlike CMI-based assays, it does not require
viable cell cultures. Considerable progress has
been made in the identiﬁcation of suitable anti-
gens, of which the most frequently studied is the
38-kDa antigen [9–11]. The sensitivity of this
antigen has been reported to be 16–80% in
various studies, depending on the smear status
of the patient and the patient population used.
Other antigens studied have included Mtb81
(malate synthase) [12], MTB48 [13], a-crystallin
(14 kDa) [10], MTC28 [10], thiol peroxidase [14],
MPT51 [10], MPT32 [15], ICDI [16], ICDII [16],
Ag85A, Ag85B [10,17] and Rv3369 [18]. Finally,
ESAT-6 and CFP-10, two antigens that have been
used for CMI-based tests, have also been evalu-
ated as targets of humoral immune responses
[10,11,19].
About 10% of the genome of M. tuberculosis
codes for proteins belonging to the PE and PPE
families [20], which are glycine-rich and essen-
tially exclusive toM. tuberculosis [21]. Few studies
support the notion that PE and PPE proteins are
of functional importance [20,22], and it is widely
speculated that they could be responsible for
generating antigenic variation [23–27]. However,
little has been documented concerning the effect
that the PPE family of proteins, each of which is
unique in its protein sequence and possible
structure, may have on the immune system, with
the exception of Rv2430c [28], Rv2608 [29] and
Rv2108 [30].
On the basis of comparative genomics of BCG
vaccines by whole genome DNA microarray
analysis [31] and antigen index calculations by
Lasergene Navigator (DNA STAR) software, the
present study used an open reading frame (ORF),
Rv3425, which is missing from BCG and all
virulent Mycobacterium bovis strains tested, and
which codes for a PPE family protein. The
importance of this protein in eliciting immune
responses was then evaluated with human sera
obtained from two well-deﬁned groups of pa-
tients: those with pulmonary TB, and those with
extra-pulmonary disease. Human sera from clin-
ically healthy individuals were used as controls to
compare the immunological responses to the
protein. The responses obtained were compared
with those obtained with two other well-known
antigens, ESAT-6 and CFP-10.
MATERIALS AND METHODS
RNA extraction and RT-PCR
RNA was extracted from 109 M. tuberculosis H37Rv cells,
cultured in Middlebrook 7H9 medium, supplemented with
albumin–dextrose complex, using a Qiaquick total RNA
extraction kit (Qiagen, Hilden, Germany), and was dissolved
in 50 lL of nuclease-free water and stored at )70C until
required. First-strand synthesis was carried out with avian
myeloblastosis virus reverse transcriptase, followed by heat
denaturation to inactivate the enzyme. Subsequent second-
strand synthesis was performed with Tﬂ polymerase. The
ampliﬁcation product was visualised by electrophoresis in an
agarose 1% w ⁄v gel. Before cDNA synthesis, the RNA was
treated with RNase-free DNase I (Boehringer, Mannheim,
Germany) at 37C for 20 min. RT-PCR was performed using
the ThermoScript RT-PCR system (Invitrogen, Carlsbad, CA,
USA), with the speciﬁc primers Rv3425-F (5¢-ATGCATC-
CAATGATACCAGC) and Rv3425-R (5¢-CTACCCGCCCCTG-
TAGATCTG), according to the manufacturer’s instructions.
Cloning, expression and puriﬁcation of the recombinant
protein Rv3425 and ESAT-6 and CFP-10
The ORFs corresponding to Rv3425 (528 bp), ESAT-6 (Rv3875,
288 bp) and CFP-10 (Rv3874, 303 bp) were ampliﬁed by PCR
from the genomic DNA of H37Rv. BamHI and HindIII restric-
tion sites were incorporated at the 5¢-end of the forward and
reverse primers, respectively, for Rv3425, ESAT-6 and CFP-10.
The primers and parameters for thermal cycle ampliﬁcation are
shown in Table 1. The amplicons comprising the full-length
Rv3425, ESAT-6 and CFP-10 ORFs were cloned at the BamHI
and HindIII sites of the cloning vector pUC18. The clones were
conﬁrmed by sequencing, using the T7 promoter primer, on a
Prism 377 DNA sequencer (Applied Biosystems, Warrington,
UK), and were then sub-cloned into the expression vector
pET32a (Invitrogen) with six N-terminal histidine sequence
tags. The constructs generated were then transformed into the
BL21-CodonPlus (DE3)-RP strain of Escherichia coli (Novagen,
Madison, WI, USA) for expression. The over-expressed His-
tagged recombinant Rv3425 and ESAT-6 proteins were puriﬁed
from the insoluble inclusion bodies contained in 1 L of
isopropyl-b-D-thiogalactopyranoside-induced batch cultures
by afﬁnity chromatography using a His-Bind Column
(Novagen) in the presence of 8 M urea, according to the
manufacturer’s recommendations, while CFP-10 was puriﬁed
under native conditions. The puriﬁed recombinant proteins
were dialysed against 20 mM Tris-HCl, pH 7.5, containing
100 mM NaCl and glycerol 3% v ⁄v, and were quantiﬁed using
Bradford’s reagent (Bio-Rad, Hemel Hempstead, UK).
Study population
In total, 110 serum samples were examined in this study. The
sera were obtained from patients in three distinct groups: (i) 50
patients (median age 44.3 years; range 19–73 years; 71.4%
males) with a diagnosis of pulmonary TB, based on clinical
signs and symptoms (fever, cough and productive sputum), a
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suggestive chest X-ray, and the presence of acid-fast bacilli
in sputum smears; (ii) 32 patients (median age 42.2 years;
range 20–75 years; 64.7% males) with a diagnosis of an
extra-pulmonary form of TB, e.g., of the lymph nodes (neck,
axillae and groin), pericardium, spine, thoracic spine, pleura,
mammae, joints or peritoneum, based on clinical signs and
symptoms and the demonstration of acid-fast bacilli in
biopsies of the affected tissues; and (iii) 28 healthy individ-
uals (median age 19.1 years; range 18–20 years; 53% males)
who had received M. bovis BCG vaccination during child-
hood. Since this study was performed on a protein from
the PPE family, members of which are unique to mycobac-
teria, cross-reactivity to this protein would not be expected,
and it was therefore considered unnecessary to include
control subjects with other bacterial infections in the present
study.
All patient serum samples were obtained from No. 6
Hospital of Zhengzhou, Henan Province, China. Blood sam-
ples were drawn from TB patients shortly after diagnosis and
initiation of treatment, while control sera were drawn from
students in Fudan University who had received BCG vaccin-
ation during childhood. Donors in this group answered a
questionnaire concerning BCG vaccination, travel history,
contact with TB patients and occupational exposure to myco-
bacteria. Subsequently, donors with known prior exposure, or
who were considered to be at risk of prior exposure, were
excluded. All donors were aged >18 years and gave informed
consent; the study was also approved by the Ethics Committee,
Ministry of Health, China. Only HIV-seronegative individuals
were included in the study.
Immunosorbent assays
ELISAs were performed to check the B-cell immune response
in humans to the Rv3425 recombinant protein and to the other
well-known antigens, ESAT-6 and CFP-10. In brief, 96-well
microtitre plates (Nalge Nunc International, Rochester, NY,
USA) were coated with 500 ng ⁄ 100 lL of either control
antigens or Rv3425, incubated overnight at 4C, washed three
times with phosphate-buffered saline, and blocked with
100 lL of blocking buffer (bovine serum albumin 2% w ⁄v in
phosphate-buffered saline) for 2 h at 37C. The plates were
then washed three times with PBST wash buffer (Tween-20
0.05% v ⁄v in 1 · phosphate-buffered saline). The sera from TB
patients belonging to different clinical groups were diluted
200-fold in blocking buffer, according to the results of the
initial standardisation experiments (results not shown). Dilu-
ted serum (50 lL) was then added to antigen-coated wells and
incubated for 1 h at 37C. The plates were thoroughly washed
with PBST and then incubated with anti-human IgG–horse-
radish peroxidase (Sigma, Poole, UK) at 37C for 1 h. Horse-
radish peroxidase activity was detected with a chromogenic
substrate, o-phenylenediamine tetrahydrochloride (Sigma),
dissolved (1 lL ⁄mL) in citrate–phosphate buffer (pH 5.4) and
H2O2. The reaction was terminated by the addition of 0.5 M
H2SO4, and absorbance values were measured at 492 nm in an
ELISA reader (Bio-Rad). Each ELISA was repeated at least
twice.
Data analysis
The ELISA results were analysed using cut-off values equal to
the mean optical density for the healthy control serum samples
plus three standard deviations. Any sample exhibiting absorb-
ance above the cut-off value was considered to be positive. For
statistical analysis, the differences between groups of TB
patients and healthy controls were calculated by the inde-
pendent-samples t-test using the Statistics Package for Social
Science (SPSS Inc., Chicago, IL, USA), with p <0.05 considered
to be signiﬁcant.
RESULTS
Expression of the hypothetical PPE ORF Rv3425
at the mRNA level
In order to verify whether the putative ORF
Rv3425 represents a functional gene, total RNA
from M. tuberculosis H37Rv was analysed by RT-
PCR with a pair of Rv3425-speciﬁc primers that
were selected to produce a 528-bp amplicon.
Table 1. PCR primers and thermal
cycle parameters for ampliﬁcation of
open reading frames
Primer Sequence PCR parameters
Amplicon
size
ESAT-6 288 bp
Forward GAC ggatcc ATG ACA GAG CAG CAG CAG TGG AAT TTC 94C for 5 min
Reverse GAC aagctt CTA TGC GAA CAT CCC AGT GAC G Then 30 cycles:
94C for 1 min
66C for 1 min;
72C for 45 s
Then 72C for 5 min
CFF-10 303 bp
Forward GAC ggatcc ATG GCA GAG ATG AAG ACC GAT GCC 94C for 5 min
Reverse GAC aagctt TCA GAA GCC CAT TTG CGA GGA CAG Then 30 cycles:
94C for 1 min;
66C for 1 min;
72C for 45 s
Then 72C for 5 min
Rv3425 528 bp
Forward GAC ggatcc ATG CAT CCA ATG ATA CCA GC 94C for 5 min
Reverse GAC aagctt CTA CCC GCC CCT GTA GAT CTG Then 30 cycles:
94C for 1 min;
65C for 1 min;
72C for 45 s
Then 72C for 5 min
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When the PCR products were analysed by
agarose gel electrophoresis, an amplicon of the
expected size was revealed. No PCR products
were detected in the absence of reverse transcrip-
tase. These data indicate that Rv3425 is expressed
during exponential growth in vitro.
Expression and puriﬁcation of M. tuberculosis
Rv3425 and ESAT-6 and CFP-10
To evaluate the antigenic ability of Rv3425, the
corresponding gene was expressed in E. coli
BL21-CodonPlus(DE3)-RP cells and puriﬁed as a
6 · His-tag fusion protein. Puriﬁed Rv3425 pro-
tein was fractionated by electrophoresis on a
polyacrylamide 12% w ⁄v gel. A single 37.5-kDa
protein (including the mass of the N-terminal
fusion domain of pET32a) was observed by
staining the gel with Coomassie Brilliant Blue
dye. There was no expression of the protein in
uninduced cells. The recombinant protein was
largely present in the insoluble fraction, and
therefore the puriﬁcation was carried out under
denaturing conditions from insoluble fractions in
the presence of 8 M urea, with a yield of 6.5 mg
of protein/L of culture. The over-expressed
N-terminal His-tagged Rv3425 protein was puri-
ﬁed to >98% homogeneity on a nickel afﬁnity
column, and was conﬁrmed by HPLC analysis.
Similarly, recombinant ESAT-6 and CFP-10 were
puriﬁed to 95–98% homogeneity, with a yield of
20.4 mg/L of culture. The recombinant proteins
were dialysed overnight and used for immuno-
reactivity analyses.
Reactivity of recombinant PPE protein Rv3425
with patient sera
Humoral immune responses directed against
Rv3425 were compared among TB patients and
BCG-vaccinated healthy controls (Fig. 1a). The
recombinant protein was used to screen the
infected and healthy sera by ELISA, with anti-
human IgG–horseradish peroxidase as conjugate.
The N-terminal fusion protein of pET32a was
negative in the ELISA assay. Most of the sera from
pulmonary TB and extra-pulmonary TB patients
showed a statistically signiﬁcant (p <0.0001)
response against recombinant Rv3425 protein
when compared with the healthy controls. Since
negligible antibody responses were obtained in
the healthy control group (Fig. 1a), it is likely that
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Fig. 1. The humoral immune responses directed against
the recombinant proteins Mtb Rv3425 (a) and control
antigens ESAT-6 (b) and CFP-10 (c) were compared among
different categories of patients and healthy controls.
Horizontal lines on each graph indicate the cut-off absorb-
ance, which was determined by the mean optical density
for the healthy control serum samples plus three standard
deviations. HC, healthy Mycobacterium bovis bacille Calm-
ette–Gue´rin-vaccinated controls; PTB, pulmonary tubercu-
losis patients; Extra-PTB, extra-pulmonary tuberculosis
patients.
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Rv3425 is expressed during the course of
M. tuberculosis infection, and that it may be
associated with disease manifestation and pro-
gression.
Immunodominant nature of Rv3425
Since most of the patients infected with TB
showed strong humoral responses against
Rv3425 compared with the healthy controls, it
was of interest to compare the responses to other
antigens, and also to evaluate whether Rv3425 is
immunodominant. Therefore, two well-known
immunodominant antigens of M. tuberculosis,
ESAT-6 (Rv3874) and CFP-10 (Rv3875), were also
tested (Fig. 1b,c). In order to compare Rv3425 to
ESAT-6 and CFP-10, the data presented in Fig. 1
were recalculated as percentages of positive sera
(Table 2). Although only 36.0% of individuals
with pulmonary TB and 34.4% of extra-pulmon-
ary TB cases showed a strong IgG antibody
response to ESAT-6, a high percentage of indi-
viduals with pulmonary TB (70.0%) and extra-
pulmonary TB (59.4%) recognised Rv3425
(Table 2). In comparison, 78.0% of individuals
with pulmonary TB and 65.6% of extra-pulmon-
ary TB cases showed a strong IgG response to
CFP-10. Thus, both pulmonary and extra-pul-
monary TB patients showed an Rv3425-speciﬁc
response equivalent to that for CFP-10 and higher
than that for ESAT-6. Thus, the results demon-
strate the immunodominant nature of the product
of the hypothetical PPE ORF Rv3425.
DISCUSSION
Serological diagnosis of TB has traditionally
been regarded as unreliable, mostly because of
the low sensitivity and speciﬁcity of the tests.
Apart from the intrinsic complexity of the
immunological and pathophysiological charac-
teristics of TB (a chronic disease that induces
predominantly cellular immunity and weak
humoral immunity), one possible explanation
for the general lack of success with most
serological tests is the complex mixture of crude
antigens used in these tests [32,33]. However,
several highly puriﬁed M. tuberculosis recombin-
ant antigens have now been described and
evaluated as serological markers for the disease.
Some of these antigens have been evaluated
extensively and have been shown to have
relatively high sensitivity and speciﬁcity for
the identiﬁcation of patients with pulmonary
TB [34–41]. These ﬁndings have revived the
concept that serological tests are feasible for the
diagnosis of TB.
Comparative hybridisation experiments using
DNA microarrays have revealed that ORFs absent
from M. bovis may be of considerable practical
utility. Diagnostic tests available currently, e.g.,
the tuberculin skin test, are unable to distinguish
between individuals infected with M. tuberculosis
and those vaccinated with BCG. This distinction
may be possible with an assay based on antigens
derived from an M. tuberculosis-speciﬁc gene [31].
The PE and PPE families, two large unrelated
protein families, occupy c. 10% of the coding
capacity of the M. tuberculosis genome, and it has
been hypothesised that these proteins represent
the principal source of antigenic variation in
M. tuberculosis [20].
The Rv3425 ORF selected for the present study
is a member of subgroup 3 of the PPE family, and
is located in RD11 [28,31]. The proteins in this
group are unrelated, except for the presence of the
common PPE domain, and show good possibilit-
ies for diagnostic use in a clinical setting. The
main objective of the present study was to
evaluate the immune features of the rRv3425
protein in comparison with ESAT-6 and CFP-10,
both of which have been used for the diagnosis of
TB, with sensitivities of 30–60% and speciﬁcities
of >96% [10,11,15,18,19].
Table 2. IgG seroreactivity of recombinant proteins in sera from tuberculosis patients and healthy controls
Recombination proteins
Pulmonary tuberculosis patients Extra-pulmonary tuberculosis patients Healthy controls
No. examined No. positivea % No. examined No. positivea % No. examined No. positivea %
CFP-10 50 39 78.0 32 21 65.6 28 1 3.6
ESAT-6 50 18 36.0 32 11 34.4 28 0 0
Rv3425 50 35 70.0 32 19 59.4 28 0 0
aPositive sera, deﬁned as cases for which the optical density (OD) generated by the patient serum was greater than the mean OD of the healthy control sera plus three standard
deviations.
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The comparative immunoreactivity of Rv3425,
ESAT-6 and CFP-10 clearly distinguished
between healthy subjects and TB patients
(p <0.0001). The negligible antibody response
obtained in the BCG-vaccinated healthy control
group suggests that Rv3425, ESAT-6 and CFP-10
can be used for diagnosis of M. tuberculosis
infection, even in geographical areas in which
BCG vaccination is used routinely. The high
sensitivity of Rv3425 for the serological diagnosis
of TB patients, which is sufﬁcient for use alone in
routine tests for the diagnosis of this disease, is of
great interest. Few recombinant proteins have
been reported to perform this well. Among the
molecules described previously, only the 38-kDa
antigen and CFP-10 have sensitivity equal to that
of Rv3425 for the diagnosis of pulmonary TB in
the absence of co-infection with HIV [10].
Although the lung is the primary site of disease
in 80–84% of TB cases, extra-pulmonary TB has
become more common with the advent of HIV
infection [42]. Extra-pulmonary TB remains an
important diagnostic and therapeutic problem.
Efforts to control the disease are currently ham-
pered by the lack of effective tools for the
detection of infected individuals, although new
diagnostic tests are being developed [43]. Bacteria
in extra-pulmonary TB cases can be present in low
numbers at inaccessible sites [42]. The present
study demonstrated that the PPE protein Rv3425
was recognised by sera from both pulmonary TB
and extra-pulmonary TB cases, and that it is an
immunodominant B-cell target antigen with
apparent diagnostic potential.
Since Rv3425 has the conserved motif of the
PPE gene family of M. tuberculosis, it is likely
that other members of the same family also serve
the same function in the bacterium. Rv3426 and
Rv3429, two close homologues of Rv3425 in
M. tuberculosis, are also present in RD11, and
their immunological potential is currently being
studied. It is inevitable that there is a homologue
in M. bovis, because Rv3425 is a member of the
PPE family, but the immunological response was
negative with healthy BCG-vaccinated individu-
als. It is interesting to speculate on the possible
use of Rv3425 and other immunodominant anti-
gens for vaccine development, and further stud-
ies are in progress to investigate the CMI
response to Rv3425, with the aim of evaluating
its use in the cellular immunity-based immuno-
diagnosis of TB.
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